This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q77.0 (achondrogenesis) | Special Copayment Reduction: V228 (ultra-rare disease) |
| B. Synonyms | Achondrogenesis, hypochondrogenesis (hypochondrogenesis), Hypochondrogenesis (type II), achondroplasia, Achondrogenesis type I (Parenti-Fraccaro), Achondrogenesis type II (Langer-Saldino) |
| C. Adult onset | Likelihood of first presentation in adulthood: very low — most cases of achondrogenesis end in intrauterine death or neonatal death (within minutes to hours after birth), and almost no surviving cases have been reported. Even in hypochondrogenesis (a milder variant of type II), most die of respiratory failure shortly after birth. |
| 1. History | 1952 first description by Parenti (type I) → 1967 additional report by Fraccaro → 1971 Langer and Saldino distinguish type II → 1994 COL2A1 gene variants identified → 2001 association of the DTDST (SLC26A2) gene with type IB elucidated. |
| 2. Causes | Type I: heterozygous variants in the SLC26A2 (DTDST) gene (type IB) or an unidentified gene (type IA). Type II: de novo dominant variants in the COL2A1 gene impairing type II collagen synthesis. Hypochondrogenesis is also a milder phenotype of COL2A1 variants. |
| 3. Genetics | Type I: autosomal recessive (SLC26A2, 5q32). Type II and hypochondrogenesis: autosomal dominant de novo (COL2A1, 12q13.11). COL2A1 variants are mostly glycine-substitution missense or splicing variants. Recurrence risk is low, but parental germline mosaicism is possible. |
| 4. General epidemiology | About 1 in 40,000~60,000 births. Type II is the most common and type I is rarer. Occurs worldwide regardless of sex or ethnicity. Domestic registrations are extremely limited, and statistics are difficult to obtain because most cases end in intrauterine or perinatal death. |
| 5. Pathophysiology | Type IB: SLC26A2 functional defect → impaired synthesis of sulfated proteoglycans → structural collapse of the cartilage extracellular matrix. Type II: COL2A1 variants → impaired type II collagen triple-helix formation → inability to form ossification centers within cartilage → complete failure of endochondral ossification of the spine, long bones, etc. |
| 6. Symptoms | Extreme limb shortening (micromelia), large head, short and narrow chest, abdominal distension, hydrops fetalis, immediate respiratory failure at birth. Type II: frontal bossing, soft skull, small ears or flat midface. |
| 7. Signs | X-ray: absent vertebral ossification (complete absence in type I, partial in type II), short and stubby long bones, rib fractures (type IA), absent or reduced ossification of the long bones. Histology: chondrocyte inclusion bodies (type IA), sparse cartilage matrix, loss of chondrocyte clusters. |
| 8. Screening | Prenatal ultrasound (14~16 weeks of gestation): extreme limb shortening, microcephaly or macrocephaly, narrow chest, hydrops. Late-pregnancy MRI as an adjunct to diagnosis. With a family history (type IB), SLC26A2 gene testing after chorionic villus sampling or amniocentesis. |
| 9. Diagnosis | Prenatal ultrasound + fetal skeletal MRI. Molecular genetics on fetal DNA or postmortem tissue: COL2A1 (type II), SLC26A2 (type IB). Integration of pathologic and X-ray findings (presence of vertebral ossification, shape of long bones). Postmortem autopsy and skeletal radiography. |
| 10. Treatment | No definitive treatment. Perinatal palliative care — pain control, respiratory support, family support. Because ventilator intubation does not change prognosis, the decision is made after thorough counseling with the family. Genetic counseling, recurrence risk assessment, and planning of prenatal diagnosis for the next pregnancy. |
| 11. Prognosis | Death in utero or from respiratory failure within minutes to hours after birth. No reports of long-term survival (extremely rare cases of short-term survival reported in the type II variant, hypochondrogenesis). Recurrence risk differs by type (25% for type IB; less than 1% for type II due to germline mosaicism). |
| 12. Prevention | Genetic counseling (recurrence risk assessment). With a family history (type IB), preimplantation genetic testing (PGT) or prenatal diagnosis. Detailed prenatal ultrasound at 14~20 weeks of gestation in high-risk pregnancies. Advance organization of a perinatal palliative care team. |
| 13. References | Superti-Furga A et al. 1996 Nature Genetics; Mundlos S 2009 Am J Med Genet; Spranger JW et al. 1974 Radiology … and 7 others |
The history of achondrogenesis began in 1952 when the Italian pathologist Ferdinando Parenti described the autopsy findings of two newborns who died shortly after birth. Parenti observed that cartilage formation was fundamentally absent in these cases and first reported this under the name 'achondrogenesis.' Later, in 1967, the Italian pediatrician Marco Fraccaro described additional similar cases, establishing the name 'achondrogenesis type 1 (Parenti-Fraccaro type).'
Achondrogenesis type 2 was named the 'Langer-Saldino type' in 1971 when Leonard O. Langer Jr. and Ralph M. Saldino of the United States described cases with distinct pathologic and radiologic features. Langer and Saldino established radiologically that types 1 and 2 differ clearly in the degree of vertebral ossification, the shape of the long bones, and the presence or absence of rib fractures. Later, Jürgen Spranger, Romaine Berdon, and others further systematized the radiologic phenotypes, and in 1974 a classification system was established that additionally distinguished type IA (Houston-Harris) and type IB (Parenti-Fraccaro, modified).
Understanding at the molecular level advanced rapidly in the 1990s. In 1994, the group of Andrea Superti-Furga in Switzerland proposed that achondrogenesis type IB and diastrophic dysplasia might arise from variants in the same gene, and in 1995 SLC26A2 (DTDST) gene variants were confirmed to be the cause of a dysplasia spectrum including type IB and atelosteogenesis type II. Meanwhile, the causative gene of achondrogenesis type II was identified as COL2A1 in 1994 by a group of collagen experts, and glycine-substitution missense variants were found to be the main cause.
Hypochondrogenesis was described as an independent disease in 1983 by Gianina Montena and Aiyer, but later studies confirmed it to be a milder phenotype within the COL2A1 variant spectrum, and it is now classified together within the achondrogenesis type II–hypochondrogenesis spectrum. This spectrum includes achondrogenesis type II (the most severe), hypochondrogenesis, and the perinatally lethal form of spondyloepiphyseal dysplasia (SEDC perinatally lethal form).
In Korea, these diseases are classified as ultra-rare perinatally lethal diseases, and with the recent spread of next-generation sequencing (NGS), capabilities for prenatal diagnosis and molecular confirmation have improved. Medical cost support is available through the Special Copayment Reduction V228 designation, but given the nature of a perinatally lethal disease, the main areas of medical intervention are perinatal palliative care and genetic counseling rather than long-term management.
Achondrogenesis is a genetically heterogeneous group of diseases, currently broadly classified into type I (type IA, type IB) and type II (including hypochondrogenesis), each caused by variants in different genes.
Type IA (Houston-Harris type): A type whose causative gene has not yet been clearly identified. It is presumed to be autosomal recessive, but some cases occur sporadically. Histologically, PAS-positive inclusion bodies are characteristically observed within chondrocytes, suggesting an abnormality of intracellular organelles (mainly the endoplasmic reticulum). Ossification of the long bones is extremely poor and rib fractures are frequent, making it more severe than the other types.
Type IB (Parenti-Fraccaro type): Caused by heterozygous or homozygous variants in the SLC26A2 (DTDST) gene. SLC26A2 is located on the long arm of chromosome 5 (5q32) and encodes a sulfate-chloride exchanger. This transporter supplies sulfate into cells; when it is defective, synthesis of sulfated proteoglycans decreases and the structure and function of the cartilage extracellular matrix are impaired. The SLC26A2 variant spectrum appears as a continuum according to phenotypic severity: achondrogenesis type IB (most severe) → atelosteogenesis type II → diastrophic dysplasia → multiple epiphyseal dysplasia (MED). Homozygous loss-of-function variants cause the most severe form, achondrogenesis type IB.
Type II (Langer-Saldino type) and Hypochondrogenesis: Caused by dominant de novo variants in the COL2A1 gene. COL2A1 is located on chromosome 12 (12q13.11) and encodes the α1 chain of type II collagen. Type II collagen is the most important structural protein in cartilage, the vitreous, the nucleus pulposus of the spine, and elsewhere; it forms a triple helix structure responsible for the mechanical cushioning function of the cartilage extracellular matrix. Among COL2A1 variants, glycine (Gly of the Gly-X-Y repeat sequence) substitution missense variants and splicing variants interfere with triple-helix assembly, so that type II collagen accumulates and is degraded in the endoplasmic reticulum or cannot be secreted into the extracellular matrix. Hypochondrogenesis is a disease within the same COL2A1 variant spectrum showing a milder phenotype than type II, with slightly more vertebral ossification and somewhat less severe limb shortening.
The final pathology common to all subtypes of achondrogenesis is the complete failure of the endochondral ossification process. Endochondral ossification is the main pathway of skeletal formation, proceeding in the order of growth plate chondrocyte differentiation → extracellular matrix mineralization → vascular invasion → osteocyte differentiation. When cartilage matrix synthesis is fundamentally impaired at any stage, this process cannot proceed, and ossification of the spine, long bones of the limbs, and ribs does not occur.
The genetic characteristics of achondrogenesis differ greatly by type, and accurate type classification is essential for family counseling and prediction of recurrence risk.
Type IB — SLC26A2 (DTDST) gene: Inheritance is autosomal recessive; when each parent is a carrier of one variant allele, there is a 25% recurrence risk in children. The SLC26A2 gene was identified in 1994 by Kornzig (Dietz et al.) and Savia (Savarirayan et al.), and about 600 pathogenic variants are registered in ClinVar. The most common variant is the R279W missense variant, frequently observed in patients of European origin. Carrier frequency is estimated at about 1/70, which explains the not inconsiderable occurrence of this spectrum of diseases.
Type II and hypochondrogenesis — COL2A1 gene: Mostly arises from de novo (new) dominant variants, and the parents are normal. Therefore, the recurrence risk is theoretically less than 1%, but a few cases have been reported in which a second affected child was born to the same parents due to germline mosaicism. Missense variants substituting the glycine (Gly) position of the Gly-X-Y repeat sequence in the COL2A1 gene are most common, and severe achondrogenesis type II is associated with glycine substitutions near the C-terminus of the triple helix. Splicing variants are more frequently associated with the hypochondrogenesis phenotype.
COL2A1 disease spectrum (type II collagenopathies): COL2A1 variants encompass a very broad phenotypic spectrum, from achondrogenesis type II to the mildest, Stickler syndrome type 1. Listed from severe to mild: achondrogenesis type II → hypochondrogenesis → perinatally lethal spondyloepiphyseal dysplasia (SEDC-perinatally lethal) → spondyloepiphyseal dysplasia (SEDc) → Kniest dysplasia → Stickler syndrome. Even with the same COL2A1 variant, the phenotype is determined by its functional consequence (dominant-negative effect vs. haploinsufficiency).
Molecular diagnosis in practice: In prenatal or postmortem diagnosis, panel-based next-generation sequencing (NGS) or clinical whole exome sequencing (WES) is used as the standard. Large deletions and duplications of the COL2A1 gene require additional confirmation by MLPA or array comparative genomic hybridization (aCGH). After molecular diagnosis is confirmed, recurrence risk in future pregnancies and prenatal diagnosis plans are established based on genotype-phenotype correlation.
Prenatal diagnosis strategy: With a family history of type IB, confirmation is possible by SLC26A2 gene analysis after chorionic villus sampling (CVS, 11~14 weeks of gestation) or amniocentesis (15~20 weeks of gestation). Preimplantation genetic testing (PGT-M) is also applicable for type IB. Because type II is mostly de novo, prenatal diagnosis in the next pregnancy is possible only when molecular diagnosis has been established in a previously affected child or an already deceased fetus.
Achondrogenesis is an ultra-rare disease belonging to the most lethal group among skeletal dysplasias. Its exact incidence is difficult to estimate because most patients die in utero or perinatally and are not included in survival statistics.
Incidence: Depending on the literature, it is estimated at 1/40,000~1/60,000 live births, but when intrauterine deaths and terminations of pregnancy are included, the actual incidence is much higher. Type II is reported 2~3 times more frequently than type I. For type IB, considering the SLC26A2 heterozygous carrier frequency (about 1/70), the theoretical birth frequency is about 1/20,000, but the actual diagnosis rate is lower.
Sex and ethnicity: There is no difference in occurrence of achondrogenesis by sex. There are no reports of higher incidence in particular ethnic groups, and it occurs sporadically in all ethnicities. In type IB, some founder mutations have been reported in patients of Mediterranean origin.
Status in Korea: Given the nature of an ultra-rare disease, the number of registered patients in Korea is extremely limited. Patients registered under Special Copayment Reduction code V228 are mainly cases confirmed by prenatal diagnosis or postmortem autopsy, and there are virtually no surviving registered patients. In the Korea Disease Control and Prevention Agency (KDCA) rare disease registry as well, about 1~5 reports of this disease are understood to be made per year. With advances in prenatal ultrasound technology enabling early detection at around 14~16 weeks of gestation, this helps with appropriate genetic counseling and perinatal management planning.
Epidemiological particularities: Achondrogenesis is closely associated with hydrops fetalis, polyhydramnios, and fetal demise. It is often discovered incidentally on prenatal ultrasound, and the management strategy varies depending on the gestational age at discovery and the availability of radiologic and molecular diagnosis. Advanced maternal age, family history, and consanguineous marriage act as factors increasing incidence in type IB. In contrast, type II arises mainly from de novo variants and therefore occurs regardless of parental age or family history.
The pathophysiology of achondrogenesis is based on the fundamental failure of endochondral ossification, the normal process of skeletal development. Most of the fetal skeleton is formed through endochondral ossification, in which mesenchymal cells form a cartilage model (cartilage anlage) that is gradually replaced by bone. In achondrogenesis, formation of the cartilage matrix itself—the starting point of this process—is impaired.
Type IB — mechanism of sulfated proteoglycan deficiency: The SLC26A2 protein is a sulfate-chloride exchanger located in the cell membrane that brings extracellular sulfate ions into the cell. Intracellular sulfate is activated to 3'-phosphoadenosine-5'-phosphosulfate (PAPS) and then used in the Golgi apparatus for sulfation of the sugar chains (GAG chains: chondroitin sulfate, heparan sulfate, keratan sulfate, etc.) attached to the core proteins of proteoglycans. Sulfated proteoglycans (aggrecan, versican, etc.) play a key role in binding water and withstanding compressive loads in the cartilage extracellular matrix. When SLC26A2 is defective, the intracellular sulfate supply decreases and proteoglycan sulfation becomes insufficient; as a result, the structural integrity of the cartilage extracellular matrix is lost and growth plate function is paralyzed.
Type II — COL2A1 variants and the mechanism of type II collagenopathy: Three pro-α1(II) chains produced from COL2A1 form a triple helix in the endoplasmic reticulum (ER) to make up procollagen II, which then forms fibrils in the extracellular matrix. When glycine in the Gly-X-Y repeat unit is substituted by a larger amino acid, triple-helix formation is delayed and disrupted, misfolded pro-α1(II) chains accumulate in the ER, and the ER stress response is activated. This induces ER-associated degradation (ERAD) and the unfolded protein response (UPR) in chondrocytes, leading to chondrocyte apoptosis and reduced matrix synthesis. In addition, the secreted abnormal collagen exerts a dominant-negative effect that disrupts fibril structure.
Common final pathway: Whichever gene is mutated, the normal composition and structure of the cartilage extracellular matrix is destroyed, and the proliferation, hypertrophy, and mineralization of growth plate chondrocytes do not proceed. As a result, the long bones (femur, humerus, tibia, etc.) form only a markedly short and thick shape, and vertebral ossification centers also fail to form, so the vertebral bodies are not seen or are seen only minimally on radiographs. Shortening of the ribs and extreme narrowing of the chest severely limit lung development, making it impossible to sustain breathing after birth.
The clinical symptoms of achondrogenesis appear from the fetal period before birth, and this disease is a perinatally lethal disease in which spontaneous breathing cannot be sustained even if the infant is born alive. The severity of clinical presentation varies somewhat by type, but extreme developmental impairment of the limbs and trunk overall is common to all types.
General appearance: The most characteristic finding is severe micromelia, in which the limbs appear abnormally short and stubby relative to the trunk. Both the upper and lower limbs are shortened uniformly in the proximal and distal segments. The head is relatively large and the trunk short, with a bulging, protruding abdomen. The face shows frontal bossing with a flat nasal bridge and prominent forehead and cheeks, giving a characteristic facial appearance.
Chest findings: The chest is extremely narrow and short, so the abdomen protrudes relatively prominently. The ribs are short and horizontally oriented, and rib fractures are frequently observed, especially in type IA. Because the thoracic volume does not meet the minimum requirement for lung development, pulmonary hypoplasia inevitably accompanies.
Head and cervical spine findings: In type II, the skull is soft and so poorly ossified that it indents when pressed with a finger. In type I, skull ossification is slightly poorer than in type II. The neck is short, or so short that it is virtually indistinguishable. In some cases, the skin of the posterior neck is present as redundant skin folds.
Prenatal fetal findings: Polyhydramnios is common during pregnancy, and hydrops fetalis may accompany. Along with fetal intrauterine growth restriction, limb shortening begins to be observed on ultrasound from around 12 weeks of gestation. Fetal movements are often weak or hard to feel. In some cases, intrauterine fetal death (IUFD) occurs before 20 weeks of gestation.
Clinical differences between type II and hypochondrogenesis: In type II, vertebral ossification is completely absent or extremely minimal, whereas in hypochondrogenesis partial ossification is observed in the thoracic and some lumbar vertebrae. Hypochondrogenesis is accompanied by midface hypoplasia, cleft palate, and a primitive lens (vitreous abnormality); the chance of survival is slightly higher than in type II, but most die within a few days.
The objective signs of achondrogenesis are confirmed by prenatal ultrasound, postnatal physical examination, radiography, and pathologic/histologic examination. Skeletal radiographic findings and pathologic findings occupy a particularly important place in the diagnosis of this disease.
Skeletal radiographic findings — type IA (Houston-Harris): The most severe type, with complete absence of ossification of the vertebral bodies, sacrum, pubic bones, and ilium. The ilium is star-shaped or small and irregular. The ribs are very short and horizontal, and rib fractures with callus formation are characteristic. The femur is extremely short, and no ossification center is observed.
Skeletal radiographic findings — type IB (Parenti-Fraccaro): Vertebral ossification is absent or extremely poor. The long bones are short and broad with a pointed lower end, showing a 'spike' shape. The iliac wings of the pelvis are horizontally flat, and ossification of the ischium and pubis is poor. The ribs are short, but fractures are less frequent than in type IA.
Skeletal radiographic findings — type II (Langer-Saldino): Vertebral ossification is completely absent or extremely minimal. The long bones are short and broad with irregular margins. There is no ossification of the ischium and pubis. The ribs are short, but fractures are rare. Ossification of the skull is poor, so it is soft and easily deformed.
Histopathologic findings: In type IA, large round PAS-positive inclusion bodies 1~5 μm in diameter are characteristically observed within chondrocytes, reflecting dilation of the endoplasmic reticulum. The cartilage matrix is hypocellular and the fibrous structure within the matrix is abnormal. In type IB there are no inclusion bodies, and sulfated proteoglycans in the cartilage matrix are markedly reduced. In type II, accumulation of procollagen II within the endoplasmic reticulum is confirmed by immunohistochemistry. On growth plate analysis, loss or marked reduction of the zone of hypertrophic chondrocytes is a common finding.
Ultrasound findings (prenatal): Detailed ultrasound at 14~16 weeks of gestation shows femur length (FL) extremely short for gestational age (-4 SD or below), marked reduction of thoracic circumference (TC), a disproportion in which head circumference (HC) is relatively large compared with abdominal circumference (AC), severe polyhydramnios, and hydrops fetalis. Doppler ultrasound evaluation of fetal circulation and observation of fetal behavior (absent or extremely rare breathing movements) are used as adjuncts.
There is no systematic screening program for achondrogenesis in the general population. Given that it is an ultra-rare and perinatally lethal disease, prenatal diagnosis targeting high-risk groups serves as the practical screening.
Prenatal ultrasound screening: Routine prenatal ultrasound for pregnant women is the most important screening method. On first-trimester (11~14 weeks) ultrasound, thick and short limbs and long bones markedly short relative to crown-rump length (CRL) may already be observed. On detailed second-trimester (18~22 weeks) ultrasound, extreme shortening of femur length (FL), narrowing of the chest, and absent vertebral ossification are the main screening indicators. In particular, when the femur length/abdominal circumference (FL/AC) ratio deviates greatly from the normal range, a lethal skeletal dysplasia should be strongly suspected.
Three-dimensional (3D) ultrasound and fetal MRI: 3D ultrasound is used as an adjunct for three-dimensional evaluation of thoracic volume and limb shape. Fetal MRI is used complementarily when ultrasound resolution is insufficient for evaluating ossification of the spine and skull, lung volume (lung/liver signal ratio), and abnormalities of brain structure.
Family history-based screening of high-risk groups: When achondrogenesis type IB was confirmed by molecular diagnosis in a previous pregnancy, SLC26A2 gene variants are analyzed directly in the next pregnancy by chorionic villus sampling (CVS) at 11~14 weeks of gestation or amniocentesis at 15~20 weeks. For type II (de novo), prenatal genetic testing is possible only when a COL2A1 variant has been confirmed in a previously affected child. Preimplantation genetic testing (PGT-M) can be performed together with in vitro fertilization when there is a verified variant in type IB.
Limitations of noninvasive prenatal testing (NIPT): Currently commercially available NIPT based on cell-free fetal DNA (cffDNA) focuses on screening for trisomies and sex chromosome abnormalities, and there is no standardized NIPT panel for achondrogenesis, a single-gene disorder. Research-based whole fetal genome analysis (cffDNA-based WES/WGS) is being attempted at some centers, but its sensitivity and clinical application are not yet at the standardization stage.
Confirmation of achondrogenesis is made by integrating prenatal ultrasound findings, fetal radiographic findings, pathologic/histologic examination, and molecular genetic analysis. Accurate type classification is essential for predicting recurrence risk and for family counseling.
Prenatal ultrasound diagnosis: Detailed ultrasound at 14~22 weeks of gestation is the starting point of diagnosis. Applying the diagnostic criteria for lethal skeletal dysplasia, femur length, thoracic circumference, abdominal circumference, head circumference ratios, vertebral shadows, and the presence of hydrops fetalis are systematically evaluated. Characteristic of achondrogenesis are femur length reduced to -4 SD or below for gestational age, a thoracic/abdominal circumference ratio markedly lower than normal, and no visible vertebral shadows.
Fetal/neonatal whole-body skeletal radiography: After birth, or in cases of death shortly after delivery, whole-body skeletal radiography (babygram) is essential. Findings of vertebral ossification, long bone shape, rib fractures, pelvic ossification, and skull ossification are integrated and used for subtype classification. When subtype classification is difficult from radiographic findings alone, pathologic and molecular tests are added.
Pathologic/histologic examination: A full autopsy including the body or the placental and umbilical cord tissues is recommended. Cartilage tissue (especially the growth plate) is sampled, and specific findings are confirmed with H&E staining, PAS staining, and immunohistochemistry (type II collagen antibody, type X collagen antibody, etc.). The PAS-positive inclusion bodies of type IA and the collagen accumulation within the endoplasmic reticulum of type II play a decisive role in diagnosis.
Molecular genetic analysis: DNA is extracted for analysis from fetal tissue (chorionic villi, amniotic fluid cells, fetal muscle/cartilage), postmortem tissue, or FFPE (formalin-fixed paraffin-embedded) blocks. Targeted analysis of the COL2A1 (type II) and SLC26A2 (type IB) genes or skeletal dysplasia gene panel analysis (panel-based NGS) is standard. If no variant is identified, testing is expanded to clinical whole exome sequencing (WES) or whole genome sequencing (WGS). When molecular diagnosis is established, analysis of parental variants allows precise prediction of recurrence risk.
Differential diagnosis: The main lethal skeletal dysplasias requiring differentiation from achondrogenesis include thanatophoric dysplasia (Q77.1), campomelic dysplasia, severe hypophosphatasia, and short rib syndrome (Q77.2). Each disease is differentiated by its characteristic radiographic findings and associated gene variants.
There is currently no definitive treatment for achondrogenesis. This disease is a perinatally lethal disease for which, with the current level of medicine, no therapeutic intervention can prolong life or enable normal development. The focus of medical response is on establishing the diagnosis, family support, perinatal palliative care, and genetic counseling for future pregnancies.
Prenatal management: When achondrogenesis is diagnosed prenatally, a multidisciplinary team—including a maternal-fetal medicine specialist, a genetic counselor, a palliative care team, a neonatal intensive care specialist, and a social worker—is formed to support the pregnant woman and family. The pregnant woman and family are given sufficient information on the prognosis of the disease, choice of delivery method (vaginal delivery vs. cesarean section), whether to perform neonatal resuscitation, and the palliative care plan, and are supported in decision-making. When polyhydramnios is severe, amnioreduction may be considered to prevent maternal dyspnea or preterm labor.
Delivery and neonatal care: The delivery method is decided considering fetal microcephaly and limb malformations, fetal presentation, and so on, and cesarean section may be necessary. After birth, the newborn shows immediate respiratory failure, and even if endotracheal intubation and mechanical ventilation are attempted, adequate gas exchange is impossible due to pulmonary hypoplasia. After thoroughly sharing in advance with the family the fact that resuscitation attempts do not change the prognosis, the family is allowed to choose whether to use a ventilator. The international recommendation is to prioritize comfortable and dignified care (comfort care) over aggressive resuscitation attempts.
Palliative care: During the short time between the baby's birth and death, pain is minimized and the parents are helped to spend sufficient time with the baby. Administration of analgesics (morphine, midazolam, etc.) to relieve pain and discomfort is the core of palliative care. Memorial activities desired by the family, such as photography, foot/hand casts, and baptism or religious rites, are supported. Obtaining consent for postmortem autopsy (or tissue sampling) and planning appropriate sample preservation for genetic testing are necessary.
Genetic counseling: After molecular diagnosis is established, comprehensive genetic counseling for the parents and extended family is essential. For type IB, it is confirmed whether both parents are carriers, and information is given on the recurrence risk in future pregnancies (25%) and methods of prenatal diagnosis (PGT, CVS, amniocentesis). For type II, because most cases are de novo, the recurrence risk is low, but the possibility of parental germline mosaicism is explained, and prenatal ultrasound and, if necessary, molecular diagnosis are recommended in the next pregnancy. Psychological support and connection with family support groups with similar experiences are also important components of genetic counseling.
The prognosis of achondrogenesis is extremely poor. By medical definition, this disease is classified as perinatally lethal, and no long-term survival cases have been reported in the world literature.
Timing and cause of death: In types IA and IB, intrauterine fetal demise (IUFD) is frequent, and even if born alive, infants die of respiratory failure within minutes to hours after birth. Type II (including hypochondrogenesis) mostly results in death shortly after birth; short-term survival of days to weeks is rarely reported in hypochondrogenesis, but there is no long-term survival. The direct cause of death is pulmonary hypoplasia due to narrowing of the chest and the resulting respiratory failure. Even when endotracheal intubation and mechanical ventilation are attempted, sufficient gas exchange is not achieved because of the mechanical restriction of the chest and failure of alveolar development.
Recurrence risk: Type IB is autosomal recessive, so when both parents are carriers there is a 25% recurrence risk in the next pregnancy. Type II is mostly de novo, so the recurrence risk is less than 1%, but recurrence risks of up to 2% have been reported due to parental germline mosaicism (when some germ cells carry the variant). Therefore, even for type II, it is standard to recommend prenatal ultrasound follow-up and, where possible, prenatal genetic testing in the next pregnancy.
Psychological impact on the family: Families who receive a diagnosis of perinatal lethality experience psychological reactions such as profound grief, guilt, anger, and depression. In particular, when the parents are confirmed to be carriers in type IB, guilt that the baby died because of their genes may be great. Immediate psychological support, grief counseling, and connection with support groups are needed after diagnosis. In Korea, support can be linked through rare disease patient and family organizations and domestic pediatric and perinatal medicine societies.
Non-necessity of long-term follow-up and ethical considerations: Because this is a perinatally lethal disease, long-term follow-up management does not apply to surviving babies. Medical staff are responsible for providing sufficient information while maintaining ethical neutrality in the decision-making processes the family goes through (whether to perform resuscitation, whether to continue the pregnancy, whether to use prenatal diagnosis). In the Korean medical setting, rare disease Special Copayment Reduction registration, a multidisciplinary approach by a perinatal palliative care team, and linkage with genetic counselors are key components of family support.
There is currently no way to completely prevent the occurrence of achondrogenesis itself. In particular, because most type II cases arise from de novo variants, preventive approaches are limited in pregnancies without a family history. However, when there is a family history (type IB) or a previously affected child, systematic prevention strategies are possible.
Genetic counseling and recurrence risk assessment: All families in which achondrogenesis was diagnosed in a previous pregnancy should receive counseling with a medical geneticist or genetic counselor. When molecular diagnosis is established, the recurrence risk by type (type IB 25%, type II 1~2%) is explained accurately, and the options when planning the next pregnancy (natural pregnancy + prenatal diagnosis, PGT, adoption, etc.) are explained neutrally.
Preimplantation genetic testing (PGT-M): In type IB, when carrier variants are confirmed in both parents, in vitro fertilization (IVF) can be combined with PGT-M to select unaffected embryos for implantation. This method is the most direct prevention strategy for preventing the birth of an affected child without termination of pregnancy. However, even after the embryo's genotype has been confirmed by PGT, it is standard to recommend additional prenatal diagnosis.
Use of prenatal diagnosis: In the next pregnancy, whether the fetus is affected can be confirmed by genetic analysis of fetal DNA at 11~14 weeks of gestation (CVS) or 15~20 weeks (amniocentesis). When molecular confirmation is difficult, skeletal dysplasia findings are evaluated early with detailed ultrasound and fetal MRI at 14~18 weeks of gestation.
Enhanced prenatal ultrasound in high-risk pregnancies: In pregnancies with a history of a previously affected child or a family history, periodic detailed ultrasound (every 2~4 weeks) is performed from early pregnancy to detect abnormal findings early. When abnormal findings are discovered, the patient is immediately referred to a specialized perinatal medicine center to receive integrated prenatal care.
Advance organization of a perinatal palliative care team: After prenatal diagnosis, a multidisciplinary team consisting of a maternal-fetal medicine specialist, a neonatal intensive care specialist, a palliative care specialist, a social worker, a psychologist, and a chaplain/religious counselor is organized in advance at the delivery hospital so that prompt and integrated support can be provided at delivery. Such advance planning helps minimize the confusion and distress experienced by the family and helps them spend their last time with the baby meaningfully.
Superti-Furga A, Hastbacka J, Wilcox WR, et al. Achondrogenesis type IB is caused by mutations in the diastrophic dysplasia sulphate transporter gene. Nature Genet. 1996;12(1):100-102. DOI: 10.1038/ng0196-100. PMID: 8528245.
Spranger JW, Langer LO, Wiedemann HR. Bone Dysplasias: An Atlas of Constitutional Disorders of Skeletal Development. Stuttgart: Gustav Fischer Verlag; 1974. (Classic radiological classification reference.)
Mundlos S. Skeletal morphogenesis. Methods Mol Biol. 2009;493:311-339. DOI: 10.1007/978-1-59745-523-7_14. PMID: 18839345.
Zankl A, Neumann L, Ignatius J, et al. Achondrogenesis type IA (Houston-Harris). Am J Med Genet A. 2005;135(2):178-183. DOI: 10.1002/ajmg.a.30715. PMID: 15887224.
Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;179(12):2393-2419. DOI: 10.1002/ajmg.a.61366. PMID: 31633310.
Bonafé L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869-2892. DOI: 10.1002/ajmg.a.37365. PMID: 26394607.
Stevenson DA, Carey JC, Byrne JL, Srisukhumbowornchai S, Feldkamp ML. Analysis of skeletal dysplasias in the Utah population. Am J Med Genet A. 2012;158A(5):1046-1054. DOI: 10.1002/ajmg.a.35327. PMID: 22499661.
Krakow D, Lachman RS, Rimoin DL. Guidelines for the prenatal diagnosis of fetal skeletal dysplasias. Genet Med. 2009;11(2):127-133. DOI: 10.1097/GIM.0b013e3181971ccb. PMID: 19265753.
Wilcox WR, Rimoin DL, Cohn DH. Achondrogenesis: recent advances in diagnosis and understanding pathogenesis. Curr Opin Pediatr. 1998;10(6):670-674. DOI: 10.1097/00008480-199812000-00016. PMID: 9866684.
Unger S, Ferreira CR, Mortier GR, et al. Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A. 2023;191(5):1164-1209. DOI: 10.1002/ajmg.a.63132. PMID: 36779427.